Sylvester investigators identify potential targets to overcome treatment resistance in TNBC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Researchers with the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and collaborators have shown that immature natural killer cells are present in patients with triple-negative breast cancer and likely promote, instead of inhibit, disease progression in this cancer type.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

FDA approved Wilserdly (giredestrant) in combination with everolimus for the treatment of adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated locally advanced or metastatic breast cancer, as detected by an FDA-authorized test, whose disease has recurred during or after completion of endocrine-based adjuvant therapy, or has progressed on at least one endocrine-based regimen in the metastatic setting.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login